Exclusive Summary

• - Reference-matching concentration/volumes (1.34 mg/mL in 1.5 mL and 3 mL) enable like-for-like switching and global dosing alignment.
• - Explosive GLP-1 demand plus ongoing originator shortages create a near-term distribution window in patent-light or exempt markets.
• - Addresses two high-burden conditions—type 2 diabetes and obesity—with proven glycemic, weight-loss, and cardiovascular benefits.
• - API compliance with US/EU recombinant DNA product standards supports ICH-style quality expectations and registrations.
• - Meaningful cost-down versus originator (typically 30–70%) improves affordability and speeds uptake in private/self-pay channels.